Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 8

1.

Evaluation of a plasmid DNA-based anthrax vaccine in rabbits, nonhuman primates and healthy adults.

Keitel WA, Treanor JJ, El Sahly HM, Evans TG, Kopper S, Whitlow V, Selinsky C, Kaslow DC, Rolland A, Smith LR, Lalor PA.

Hum Vaccin. 2009 Aug;5(8):536-44. Epub 2009 Aug 14.

2.

Progress and novel strategies in vaccine development and treatment of anthrax.

Chitlaru T, Altboum Z, Reuveny S, Shafferman A.

Immunol Rev. 2011 Jan;239(1):221-36. doi: 10.1111/j.1600-065X.2010.00969.x. Review.

PMID:
21198675
3.

Anthrax vaccination strategies.

Cybulski RJ Jr, Sanz P, O'Brien AD.

Mol Aspects Med. 2009 Dec;30(6):490-502. doi: 10.1016/j.mam.2009.08.006. Epub 2009 Sep 1. Review.

4.

Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax.

Schneemann A, Manchester M.

Future Microbiol. 2009 Feb;4(1):35-43. doi: 10.2217/17460913.4.1.35. Review.

5.

Rabbit and nonhuman primate models of toxin-targeting human anthrax vaccines.

Phipps AJ, Premanandan C, Barnewall RE, Lairmore MD.

Microbiol Mol Biol Rev. 2004 Dec;68(4):617-29. Review.

6.

Licensure strategy for pre- and post-exposure prophylaxis of biothrax vaccine: the first vaccine licensed using the FDA animal rule.

Longstreth J, Skiadopoulos MH, Hopkins RJ.

Expert Rev Vaccines. 2016 Dec;15(12):1467-1479. Review.

PMID:
27792416
7.

Recent developments in the understanding and use of anthrax vaccine adsorbed: achieving more with less.

Schiffer JM, McNeil MM, Quinn CP.

Expert Rev Vaccines. 2016 Sep;15(9):1151-62. doi: 10.1586/14760584.2016.1162104. Epub 2016 Mar 25. Review.

PMID:
26942655
8.

Obiltoxaximab: First Global Approval.

Greig SL.

Drugs. 2016 May;76(7):823-30. doi: 10.1007/s40265-016-0577-0. Review.

PMID:
27085536

Supplemental Content

Support Center